Side by side

1. 1.Competitively blocks the bradykinin B2 receptor on blood vessels.
2. 2.Stops bradykinin-driven leakage of fluid into tissue.
3. 3.Attacks in hereditary angioedema come from uncontrolled bradykinin production when C1 inhibitor is low or faulty.
4. 4.Relief of swelling begins within about an hour in trials.
5. 5.Does not affect histamine pathways, so it is not useful in allergic reactions.

• Acute attacks of hereditary angioedema types 1 and 2 (FAST trials)
• Self-administration at home
• Laryngeal attacks - always with medical support

• Median time to first symptom relief around 2 hours in FAST-3 versus about 20 hours for placebo
• Median time to complete resolution of symptoms of roughly 8 to 10 hours
• No effect on the underlying C1 inhibitor deficiency
• Repeated doses may be needed for recurrence after about 48 hours

• Injection-site reactions, very common and often described as burning
• Headache
• Nausea
• Dizziness and fever
• Rare hypersensitivity

Research context only - prescription medicine. Licensed dosing is 30 mg subcutaneously into the abdomen, repeated after at least 6 hours if the attack persists, with a maximum of three doses in 24 hours; FAST-3 measured time to symptom relief using a composite visual analogue score.

Research context only